Pharma’s Almanac: CEO Dave Johnson shares his thoughts in Roundtable: What technology do you foresee leading the industry over the coming decade, both in terms of real approvals and general impact?

The development and rapid advancement of massively parallel sequencing technologies and analytical tools was a major breakthrough for the industry over the 2000s. This technology provided vast volumes of genotypic and phenotypic data, leading to a better understanding of human diseases. A more recent breakthrough is the development of single-cell “omics” technologies, which allow for the sequencing of DNA, RNA, proteins, and epigenetic profiles of individual cells. This has driven the discovery of rare and previously unknown cells and molecules with significant therapeutic potential and previously unknown cellular states and cellular interactions.

Read the full story.